Natera (NASDAQ:NTRA) Insider John Fesko Sells 707 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 707 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total value of $144,319.91. Following the completion of the transaction, the insider owned 189,199 shares of the company’s stock, valued at $38,621,191.87. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

John Fesko also recently made the following trade(s):

• On Tuesday, February 3rd, John Fesko sold 3,594 shares of Natera stock. The stock was sold at an average price of $231.02, for a total value of $830,285.88.
• On Wednesday, January 28th, John Fesko sold 928 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $220,548.48.
• On Tuesday, January 27th, John Fesko sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total value of $188,575.52.
• On Wednesday, January 21st, John Fesko sold 339 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $79,665.00.
• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The shares were sold at an average price of $234.74, for a total value of $4,179,780.44.

Natera Price Performance

NASDAQ NTRA traded down $1.79 during trading hours on Thursday, reaching $194.82. The company’s stock had a trading volume of 101,539 shares, compared to its average volume of 1,163,046. The firm has a fifty day simple moving average of $221.32 and a 200-day simple moving average of $206.07. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The stock has a market cap of $27.61 billion, a P/E ratio of -127.64 and a beta of 1.65.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The firm had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. During the same period in the previous year, the firm posted ($0.41) EPS. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Reflection Asset Management bought a new position in Natera in the fourth quarter worth approximately $29,000. Palladiem LLC bought a new stake in shares of Natera during the fourth quarter valued at approximately $31,000. Bank of Jackson Hole Trust increased its holdings in shares of Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Natera during the fourth quarter worth approximately $39,000. Finally, Flagship Harbor Advisors LLC bought a new position in shares of Natera in the 4th quarter worth $41,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: MyOme announced the Zenith™ portfolio with Natera and launched long‑read methylation analysis at ACMG 2026 — a commercial/technology collaboration that could broaden Natera’s rare‑disease whole‑genome and epigenetic testing capabilities and help expand addressable market and clinical utility over time. MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
• Neutral Sentiment: Natera presented at the Leerink Global Healthcare Conference (transcript available). Management commentary in the presentation could provide useful color on product launches, adoption trends, and margin/reimbursement dynamics — read for guidance but the transcript itself is informational rather than catalytic. Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Significant insider selling disclosed: CEO Steven Leonard Chapman sold 5,623 shares (~$1.15M at ~$204.13) and reduced his stake ~3.47%; other insiders (CFO Michael Brophy, John Fesko, Solomon Moshkevich) also sold smaller positions. Multiple insider sales on the same date increase perceived near‑term selling risk and likely explain part of downward pressure on the shares. SEC Form 4 — CEO Sale

Analysts Set New Price Targets

NTRA has been the subject of a number of recent research reports. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Guggenheim lifted their price objective on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a report on Monday, January 12th. Finally, JPMorgan Chase & Co. increased their target price on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.